Henry Schein, Inc. $HSIC Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 14.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 104,740 shares of the company’s stock after buying an additional 13,441 shares during the period. Envestnet Asset Management Inc.’s holdings in Henry Schein were worth $6,952,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC boosted its position in Henry Schein by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock worth $341,000 after purchasing an additional 157 shares during the period. CW Advisors LLC boosted its stake in shares of Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after purchasing an additional 163 shares during the period. Truist Financial Corp grew its holdings in Henry Schein by 3.3% during the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after purchasing an additional 175 shares in the last quarter. Simon Quick Advisors LLC increased its stake in Henry Schein by 5.5% during the 2nd quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after buying an additional 182 shares during the period. Finally, Claret Asset Management Corp lifted its holdings in Henry Schein by 6.3% in the 2nd quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after buying an additional 187 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on HSIC shares. Wells Fargo & Company raised their target price on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Evercore lifted their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Barclays initiated coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price on the stock. Mizuho set a $81.00 price target on shares of Henry Schein and gave the stock a “neutral” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $76.42.

Henry Schein Trading Up 3.6%

NASDAQ:HSIC opened at $79.57 on Friday. The firm has a market capitalization of $9.37 billion, a P/E ratio of 25.18, a P/E/G ratio of 2.28 and a beta of 0.88. The business has a 50 day simple moving average of $77.37 and a 200 day simple moving average of $71.59. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.80.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.